EA201370003A1 - Способ прогнозирования терапевтического ответа у пациентов с рассеянным склерозом - Google Patents
Способ прогнозирования терапевтического ответа у пациентов с рассеянным склерозомInfo
- Publication number
- EA201370003A1 EA201370003A1 EA201370003A EA201370003A EA201370003A1 EA 201370003 A1 EA201370003 A1 EA 201370003A1 EA 201370003 A EA201370003 A EA 201370003A EA 201370003 A EA201370003 A EA 201370003A EA 201370003 A1 EA201370003 A1 EA 201370003A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- multiple sclerosis
- patients
- therapeutic response
- interferon
- patient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Предусматривается способ для определения эффективности терапии интерфероном-бета (IFN-β) у пациента с рассеянным склерозом. Один этап способа может включать взятие биологического образца у пациента. После взятия биологического образца может быть определен уровень экспрессии по меньшей мере одного интерферон-регулируемого гена и/или его варианта. Повышенная или пониженная экспрессия по меньшей мере одного интерферон-регулируемого гена и/или его варианта по сравнению с контрольным вариантом может указывать на то, что у пациента будет достигнут слабый ответ на IFN-β-терапию.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35626510P | 2010-06-18 | 2010-06-18 | |
PCT/US2011/040810 WO2011159970A2 (en) | 2010-06-18 | 2011-06-17 | Method for predicting a therapy response in subjects with multiple sclerosis |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201370003A1 true EA201370003A1 (ru) | 2013-06-28 |
Family
ID=45348885
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201370003A EA201370003A1 (ru) | 2010-06-18 | 2011-06-17 | Способ прогнозирования терапевтического ответа у пациентов с рассеянным склерозом |
Country Status (22)
Country | Link |
---|---|
US (1) | US20130089519A1 (ru) |
EP (1) | EP2585100A4 (ru) |
JP (1) | JP2013534419A (ru) |
KR (1) | KR20130036046A (ru) |
CN (1) | CN103140235A (ru) |
AU (1) | AU2011268223B2 (ru) |
BR (1) | BR112012032344A2 (ru) |
CA (1) | CA2802999A1 (ru) |
CL (1) | CL2012003571A1 (ru) |
CO (1) | CO6670574A2 (ru) |
CR (1) | CR20130018A (ru) |
DO (1) | DOP2012000316A (ru) |
EA (1) | EA201370003A1 (ru) |
EC (1) | ECSP13012390A (ru) |
MA (1) | MA34381B1 (ru) |
MX (1) | MX2012015028A (ru) |
NI (1) | NI201200188A (ru) |
PE (1) | PE20130645A1 (ru) |
SG (1) | SG186393A1 (ru) |
TN (1) | TN2012000607A1 (ru) |
WO (1) | WO2011159970A2 (ru) |
ZA (1) | ZA201300019B (ru) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015063769A1 (en) * | 2013-11-01 | 2015-05-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Diagnostic methods and kits for determining a personalized treatment regimen for a subject suffering from a pathologic disorder |
EP3362168A1 (en) * | 2015-10-14 | 2018-08-22 | Novozymes A/S | Cleaning of water filtration membranes |
CN108304912B (zh) * | 2017-12-29 | 2020-12-29 | 北京理工大学 | 一种运用抑制信号实现脉冲神经网络监督学习的系统和方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60209832T2 (de) * | 2002-05-29 | 2007-01-25 | Charité - Universitätsmedizin Berlin | Verfahren zur Identifizierung von auf Ifn-Beta ansprechenden multiple Sklerose Patienten, durch die Bestimmung der Expression von Trail |
WO2005108610A2 (en) * | 2004-04-05 | 2005-11-17 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Methods for the selection of subjects for multiple sclerosis therapy |
US20100209914A1 (en) * | 2007-05-25 | 2010-08-19 | Ore Pharmaceuticals , Inc. | Methods, systems, and kits for evaluating multiple sclerosis |
EP2009440A1 (en) * | 2007-06-01 | 2008-12-31 | Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg | Means and methods for classifying samples of multiple sclerosis patients. |
EP2334815A4 (en) * | 2008-09-16 | 2012-06-20 | Bayer Healthcare Llc | INTERFERON RESPONSE IN CLINICAL SAMPLES (IRIS) |
-
2011
- 2011-06-17 AU AU2011268223A patent/AU2011268223B2/en not_active Expired - Fee Related
- 2011-06-17 EP EP11796478.3A patent/EP2585100A4/en not_active Withdrawn
- 2011-06-17 SG SG2012093290A patent/SG186393A1/en unknown
- 2011-06-17 CN CN2011800361199A patent/CN103140235A/zh active Pending
- 2011-06-17 WO PCT/US2011/040810 patent/WO2011159970A2/en active Application Filing
- 2011-06-17 MA MA35568A patent/MA34381B1/fr unknown
- 2011-06-17 PE PE2012002453A patent/PE20130645A1/es not_active Application Discontinuation
- 2011-06-17 MX MX2012015028A patent/MX2012015028A/es not_active Application Discontinuation
- 2011-06-17 EA EA201370003A patent/EA201370003A1/ru unknown
- 2011-06-17 BR BR112012032344A patent/BR112012032344A2/pt not_active Application Discontinuation
- 2011-06-17 JP JP2013515535A patent/JP2013534419A/ja active Pending
- 2011-06-17 CA CA2802999A patent/CA2802999A1/en not_active Abandoned
- 2011-06-17 US US13/704,752 patent/US20130089519A1/en not_active Abandoned
- 2011-06-17 KR KR1020137001149A patent/KR20130036046A/ko not_active Application Discontinuation
-
2012
- 2012-12-18 CL CL2012003571A patent/CL2012003571A1/es unknown
- 2012-12-18 NI NI201200188A patent/NI201200188A/es unknown
- 2012-12-18 DO DO2012000316A patent/DOP2012000316A/es unknown
- 2012-12-18 TN TNP2012000607A patent/TN2012000607A1/en unknown
-
2013
- 2013-01-02 ZA ZA2013/00019A patent/ZA201300019B/en unknown
- 2013-01-16 EC ECSP13012390 patent/ECSP13012390A/es unknown
- 2013-01-16 CO CO13007454A patent/CO6670574A2/es not_active Application Discontinuation
- 2013-01-17 CR CR20130018A patent/CR20130018A/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2011268223B2 (en) | 2014-05-29 |
CO6670574A2 (es) | 2013-05-15 |
CN103140235A (zh) | 2013-06-05 |
SG186393A1 (en) | 2013-01-30 |
JP2013534419A (ja) | 2013-09-05 |
BR112012032344A2 (pt) | 2017-05-30 |
WO2011159970A2 (en) | 2011-12-22 |
ECSP13012390A (es) | 2013-04-30 |
ZA201300019B (en) | 2014-03-26 |
CA2802999A1 (en) | 2011-12-22 |
WO2011159970A3 (en) | 2012-04-19 |
EP2585100A2 (en) | 2013-05-01 |
EP2585100A4 (en) | 2013-11-06 |
CL2012003571A1 (es) | 2013-08-23 |
KR20130036046A (ko) | 2013-04-09 |
MX2012015028A (es) | 2013-06-13 |
NI201200188A (es) | 2013-04-15 |
US20130089519A1 (en) | 2013-04-11 |
MA34381B1 (fr) | 2013-07-03 |
CR20130018A (es) | 2013-04-26 |
PE20130645A1 (es) | 2013-07-03 |
TN2012000607A1 (en) | 2014-04-01 |
AU2011268223A1 (en) | 2013-01-31 |
DOP2012000316A (es) | 2013-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201201657A1 (ru) | Лечение диабета | |
UY32177A (es) | Tratamiento de diabetes en pacientes con control glucémico insuficiente a pesar de la terapia con fármaco, oral o no, antidiabético | |
DK2903616T3 (da) | Anvendelse af masitinib i kombination med gemcitabin til behandling af en undergruppe af patienter, der lider af pankreascancer | |
EA201170149A1 (ru) | Новые аналоги инсулина пролонгированной активности | |
NZ609493A (en) | Diagnosis and treatments relating to th2 inhibition | |
EA200971053A1 (ru) | Способы лечения кожных язв | |
MX2013003929A (es) | Biomarcadores de citoquina como marcadores predictivos de respuesta clinica para acetato de glatiramer. | |
WO2011156468A8 (en) | A method of predicting clinical outcomes for melanoma patients using circulating melanoma cells in blood | |
WO2016201450A3 (en) | Cancer treatment and diagnosis | |
NZ701715A (en) | Means and methods for treating dlbcl | |
MA32274B1 (fr) | Thérapie antivirale | |
MX2010006090A (es) | Biomarcadores para predecir la sensibilidad de las celulas ante compuestos inmunomoduladores durante el tratamiento de linfoma de no hodgkin. | |
NZ754427A (en) | Regulation of glucose metabolism using anti-cgrp antibodies | |
EA201370003A1 (ru) | Способ прогнозирования терапевтического ответа у пациентов с рассеянным склерозом | |
EP2589665A4 (en) | METHOD FOR PREDICTING THE THERAPEUTIC EFFECT OF IMMUNOTHERAPY ON CANCER PATIENT, AND SET OF GENES AND KIT FOR USE IN THE METHOD | |
DK1778834T5 (da) | Fremgangsmåder til anvendelse af regenerative celler i behandlingen af renale sygdomme og lidelser | |
EA201300410A1 (ru) | Стратификация страдающих раком пациентов по чувствительности к терапии с использованием ингибиторов ptk2 | |
Glauche | Therapy of chronic myeloid leukaemia: simulation studies of different treatment combinations and patient-specific risk estimation | |
Li | Understand and Therapeutically Modulate the Stability of Regulatory T Cells | |
Han et al. | Effects of a Natural Contact Program on Decreasing Self-Stigma among Individuals with Schizophrenia in Taiwan | |
RU2011119308A (ru) | Способ прогнозирования эффективности лечения больных раком носоглотки | |
UA99717U (uk) | Спосіб прогнозування досягнення цільового артеріального тиску у хворих з артеріальною гіпертензією та цукровим діабетом | |
RU2007100753A (ru) | Способ прогнозирования стабильной ремиссии при проведении противовирусной терапии у больных острым гепатитом с | |
Naveed et al. | A66 AIRWAY REMODELING: WHAT'S GOING ON?: A Study Of Mechanism Of Airway Remodeling In Asthma: Mast Cell Proteases Stimulate Matrix Metalloproteinase (mmp-1) Activation And Human Airway Smooth Muscle Growth | |
Oh et al. | Commentary: effect of pregabalin on acid-induced oesophageal hypersensitivity. |